"Would the company sit on bad results in the hope of cancelling them out with great results - I would think so."
As pointed out by @Far Away Red there are continuous disclosure requirements - MSB can't sit on a known outcome.
I think the "early" raising of COVID-19 ARDS manufacturing cash was a hedge against less-than-stellar CHF or CLBP results that may have short-term downward pressure on the share price. So MSB can provide results without risking execution (to get through all the doors), regardless of how good or bad any individual result is.
Worst case for investors is share price volatility, potential for share price to go down before it goes up (assuming at least one of our "doors" has the money behind it).
MSB Price at posting:
$3.83 Sentiment: Hold Disclosure: Held
(20min delay)